NCT05383560View on ClinicalTrials.gov

Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

September 5, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
COVID-19 PandemicImmunogenicitySARS CoV 2 InfectionCOVID-19
Interventions
BIOLOGICAL

mRNA-1273.214 Vaccine

Omicron Variant-Matched Vaccine

BIOLOGICAL

MRNA-1273 Vaccine

Moderna's commercial COVID-19 Vaccine

BIOLOGICAL

Placebo

Normal Saline for injection

BIOLOGICAL

MRNA-1273.222 Vaccine

Moderna's commercial COVID-19 Vaccine

Trial Locations (1)

5265601

Sheba Medical Center, Ramat Gan

All Listed Sponsors
collaborator

ModernaTX, Inc.

INDUSTRY

lead

Sheba Medical Center

OTHER_GOV